CommercialAdministrativeLow impact
08.01.57a, Lutathera® (Lutetium Lu 177 Dotatate) (Independence Administrators)
Independence Blue Cross·Oncology, Nuclear Medicine·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
The Independence Administrators policy for Lutathera® (Lutetium Lu 177 Dotatate) has been reissued with an effective date of April 1, 2026. This is a pharmacy policy update for this specialized radiopharmaceutical used in neuroendocrine tumor treatment.
Action Required
By March 31, 2026: Review updated Lutathera® policy requirements with oncology billing team. Verify current prior authorization and documentation requirements remain unchanged for Independence Administrators members receiving this radiopharmaceutical therapy.